Yifan Pharmaceutical (002019.SZ) released its performance in the first half of the year, with a net profit attributable to shareholders of 304 million yuan, an increase of 19.91% year-on-year.

Financial news from Zhitong Finance APP, Yifan Medicine (002019.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating income of 2.635 billion yuan, a year-on-year increase of 0.11%. The net profit attributable to shareholders of the listed company was 304 million yuan, a year-on-year increase of 19.91%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 237 million yuan, a year-on-year increase of 32.21%. The basic earnings per share was 0.25 yuan.